Cirrhosis of the Liver: A Case Report and Literature Review of a Rare Case Presentation of Autoimmune Hepatitis With Systemic Sclerosis

Shashank Banait 1, Chetan Burriwar 2, Jyoti Jain 3, Priti G. Verma 3, Tanvi Banait 4, Madhura Joshi 2

1. Department of Ophthalmology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, (Deemed to be University), Wardha, IND 2. Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Wardha, IND 3. Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, (Deemed to be University), Wardha, IND 4. Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, (Deemed to be University), Wardha, IND

Corresponding author: Jyoti Jain, jyotijain@mgims.ac.in

Abstract

Systemic sclerosis (SSc) is a chronic systemic disease that affects the skin, heart, lungs, kidneys, gastrointestinal tract, and musculoskeletal system. Although gastrointestinal involvement has been reported in approximately 90% of scleroderma patients, liver involvement is uncommon. A 51-year-old female was admitted to the hospital due to abdominal distension and pedal edema. She had a history of Raynaud’s syndrome and multiple hypopigmented and hyperpigmented patches over her body for the last year. Her ascitic fluid analysis was transudative with a serum ascites albumin gradient >1.1, and the abdomen and pelvis ultrasonography reported liver cirrhosis with splenomegaly with periportal varices. Her antinuclear antibody and anti-centromere antibody were positive. Skin thickening was visible. Her alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum globulin were raised. Viral serology was negative. We managed her with diuretics, beta-blockers, prednisolone (30 mg/day administered orally), angiotensin-converting enzyme inhibitors, and calcium channel blockers. Edema and abdominal distension decreased with this management, and no Raynaud’s phenomenon was observed during the hospital stay.

Introduction

Systemic sclerosis (SSc) is a rare chronic disorder of unknown etiology, characterized by diffuse fibrosis and generalized vascular abnormalities in the skin, joints, and internal organs, leading to the failure of these organs. The etiology of SSc is multifactorial, with multiple genetic, endogenous, and exogenous factors appearing to interact with disease development. The pathogenesis of fibrosis is complex and is due to the interaction between immunological events and vascular changes, which activate fibrogenic fibroblasts [1]. Autoimmune hepatitis is a chronic inflammation of the liver characterized by the presence of autoantibodies and raised serum globulin levels. It is predominantly a disease that affects women and can present at any age. The disease may begin as acute hepatitis, which may progress to cirrhosis [2]. It is commonly associated with various autoimmune diseases, like autoimmune thyroiditis, type 1 diabetes mellitus, glomerulonephritis, ulcerative colitis, autoimmune hemolytic anemia, and autoimmune thrombocytopenia. However, its association with systemic connective tissue disorders like SSc, systemic lupus erythematosus, and mixed connective tissue disorders is infrequent [3,4]. Here, we report the case of a patient presenting with cirrhosis of the liver due to autoimmune hepatitis along with systemic sclerosis.

Case Presentation

A 51-year-old non-obese female with no history of alcoholism was admitted with complaints of gradually progressive abdominal distension and swelling over both lower limbs for the last month. She had difficulty swallowing 15 days before the presentation, which was gradual and worse with solid food. She had a history of multiple small hypopigmented and hyperpigmented patches around the neck, over the back, forearms, and legs for one year. She also presented with Raynaud’s phenomenon, which was characterized by bluish discoloration followed by diffuse pain in her fingers since last year, especially during contact with water. However, there was no history of joint pain or deformity, morning stiffness, fever, pain in the abdomen, diarrhea, constipation, chest pain, or paroxysmal nocturnal dyspnea or orthopnea. There was no past history of any neurological deficit like dysarthria, gait abnormalities, dystonia, tremors, diabetes, hypertension, dyslipidemia, metabolic syndrome, rheumatic heart disease, or ischemic heart disease. A family history of liver cirrhosis or any chronic liver disease was obtained to rule out hereditary hemochromatosis, as well as red skin lesions and epistaxis for hereditary hemorrhagic telangiectasia, which were all negative.
On general examination, she was conscious, afebrile, and pale, with a pulse rate of 100/min and blood pressure of 110/80 mmHg. She was anicteric, and bilateral pitting pedal edema up to the knee was present. Salt and pepper pigmentation around the neck, over the back, forearms, and legs was present (Figure 1).

FIGURE 1: Photographs of the patient show the salt and pepper pigmentation on the skin over the neck, back, forearm, and both legs.

Skin distal to the metacarpophalangeal joint in the hands and at the elbow was tight, but there were no ulcers, swollen fingertips, calcinosis, sclerodactyly, or telangiectasia (Figure 2).

FIGURE 2: Photographs of the patient show thickening of the skin over the hand and changes in sclerodactyly.

On systemic examination, the abdomen was distended with full flanks, the umbilicus was everted, fluid thrill and shifting dullness were present, and the liver was not palpable, but splenomegaly was present. The rest of the systemic (cardiovascular, respiratory, and central nervous system) examination did not reveal any abnormalities. On slit-lamp examination of the anterior chamber of the eyes, the Kayser-Fleischer (KF) ring was absent. Her hemogram revealed a hemoglobin of 9.6 g/dl, anisopoikilocytosis, microcytic hypochromic red blood corpuscles with a mean corpuscular volume of 71, a white blood corpuscle count of 3.88 with 77.1% granulocytes, and reduced platelets of 0.68 lac/ul. Her liver function tests showed hypoalbuminemia (2.44 gm/dl), hypergammaglobulinemia (4.08 gm/dl), and raised alanine aminotransferase (ALT) of 127 IU/L and aspartate aminotransferase (AST) of 276 IU/L with normal bilirubin and alkaline phosphatase (73 IU/L). Other parameters like blood sugar, serum electrolytes, lipid profile, kidney function tests, and electrocardiogram were normal. Her ascitic fluid was transudative in nature with a serum ascites albumin gradient of 1.35. Her blood, urine, and ascitic fluid cultures did not show the growth of any bacteria. The presence of bilateral pitting pedal edema, ascites, splenomegaly, hypoalbuminemia, and a serum ascites albumin gradient of 1.35 led to the diagnosis of liver cirrhosis with portal hypertension [5,6].

Ultrasonography of the abdomen showed a small-sized (9.7 cm) shrunken liver with coarsened echotexture of parenchyma with irregular margins, suggestive of liver cirrhosis with gross ascites, periportal fibrosis, and
splenomegaly (14.1 cm), a dilated portal vein of 12 mm with the normal color flow on Doppler imaging, a
dilated splenic vein of 15 mm, and a partially distended gall bladder. The common bile duct and intra-
hepatic biliary radicals were normal (Figure 3).

FIGURE 3: Ultrasonography of the abdomen and pelvis of the patient showed (A) a normal gallbladder with no dilatation; (B) evidence of a small-sized (9.7 cm), shrunken liver with coarsened echotexture of parenchyma and irregular margins with a normal biliary tree; (C) portal vein dilation (12 mm); (D) normal blood flow in the portal vein on color doppler imaging.

Her fibroscan of the liver could not be done due to the unavailability of this facility at our rural hospital. Her viral serology, hepatitis B surface antigen (HBsAg) for hepatitis B, antibody to hepatitis C virus (anti-HCV), and quantitative hepatitis C virus ribonucleic acid (HCV RNA) by polymerase chain reaction (PCR) and human immunodeficiency virus (HIV) infection test by enzyme-linked immunosorbent assay (ELISA) method were negative. Her serum ferritin of 69 ng/ml, serum ceruloplasmin of 30 mg/dL, and 24-hour urinary copper of 20 µg/day were normal. Her anti-mitochondrial antibodies were negative. Antinuclear antibody 17 profile blot (ANA17B) and anti-centromere antibody with a class index of four were positive (Figure 4).
FIGURE 4: The report of the immunological profile of the patient.

On the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for the classification of SSc (2013), her total score was 15. (nine for skin thickening and three each for Raynaud’s phenomenon and positive anti-centromere antibody [7]. A liver biopsy could not be performed as the patient did not give consent.

The provisional diagnosis of SSc with autoimmune hepatitis leading to cirrhosis of the liver was considered as per the international autoimmune hepatitis group diagnostic criteria [2] (Table 1).

| Diagnostic criteria                                      | Patient values                                                                                                                                                                                                 |
|----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. A minimum of one elevated ALT or AST > twice the upper limit of the normal reference range | Her ALT and AST were raised > two times the upper limit of the reference range.                                                                                                                                 |
| 2. A minimum of one positive laboratory test (elevated gamma globulin or positive ANA/ASMA) or anti-LKM-1 | She had hypergammaglobulinemia and a positive ANA. We were unable to conduct ASMA and anti-LKM-1 antibody assays due to financial constraints.                                                               |
| 3. Exclusion of other cirrhosis etiologies               | We excluded chronic viral hepatitis (hepatitis B and C), alcoholic liver disease, hemochromatosis, non-alcoholic fatty liver disease, primary sclerosing cholangitis, biliary cirrhosis, right-sided heart failure, medications (e.g., methotrexate and isoniazid), Wilson's disease, alpha-1 antitrypsin deficiency, celiac disease, polycystic liver disease, hereditary hemorrhagic telangiectasia, idiopathic adulthood ductopenia, granulomatous liver disease, infection (e.g., brucellosis, and echinococciosis) on the basis of history, examination and or biochemical, immunological, and radiological investigations. |

TABLE 1: Diagnostic criteria for autoimmune hepatitis (international autoimmune hepatitis group).

ALT: alanine aminotransferase; ANA: antinuclear antibody; Anti - LKM - 1: Anti – Liver kidney microsomal – 1 antibody; ASMA: anti-smooth muscle antibody; AST: aspartate aminotransferase.

She was managed with diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and steroids. She showed significant improvement in her symptoms; her edema and abdominal
distension decreased, and no Raynaud’s phenomenon was observed during the hospital stay.

**Discussion**

Systemic sclerosis is a multisystem disorder that primarily affects the skin, heart, lungs, gastrointestinal tract, musculoskeletal system, and kidneys. The disease is characterized by tissue fibrosis, vasculopathy, and an autoimmune response associated with specific autoantibodies. Gastrointestinal involvement is common, up to 95% [8]. However, the liver is rarely involved in this disease. As shown in the review, eight (1.1%) of 727 patients with scleroderma had involvement of the liver [9]. Primary biliary cirrhosis is the most commonly found hepatic disease in patients with SSc, while autoimmune hepatitis is rare [10,11,12].

Although the pathogenesis of the development of autoimmune hepatitis in patients with SSc is still unclear, it may be due to a dysregulated response of the cellular and humoral immune systems. According to the literature, anti-centromere antibodies are found in 3-15% of patients with autoimmune hepatitis [1,9]. Our patient was diagnosed with autoimmune hepatitis according to the criteria proposed by the international autoimmune hepatitis group, and she fulfilled all the diagnostic criteria as mentioned in Table 1 [2,13].

A few cases of autoimmune hepatitis without primary biliary cirrhosis in SSc patients have been reported. In three cases, SSc was diagnosed before the development of autoimmune hepatitis, while in one case, both conditions were diagnosed simultaneously [14-17]. The clinical characteristics of five patients and their laboratory profiles, along with the patients described in the current report, are summarized in Table 2.
### TABLE 2: Clinical characteristics of autoimmune hepatitis cases with systemic sclerosis described in English literature and chosen for this study.

| Author [Reference] | Present case | You et al [14] | Marie et al. [15] | Marie et al. [15] | Ishikawa et al. [16] | Yabe et al. [17] |
|--------------------|-------------|----------------|------------------|------------------|---------------------|------------------|
| Year of publication | 2012 | 2001 | 2001 | 1995 | 1992 |
| Country | India | Korea | France | France | Japan | Japan |
| Age/Sex | 51/ Female | 51/ Female | 67/ Female | 48/ Female | 48/ Female | 51/ Female |
| Presenting symptoms | Abdominal distension, swelling over both lower limbs, Raynaud’s phenomena, dysphagia | Hematemia, Raynaud’s phenomena | Raynaud’s phenomena, arthralgia, pain in the right hypochondrium | Raynaud’s phenomena, arthralgia | Raynaud’s phenomena, fatigue, digital ulcer |
| Clinical findings | Diffuse SSc, pedal edema, ascites, splenomegaly | Limited SSc | CREST syndrome | CRST syndrome | CREST syndrome | CREST syndrome, Jaundice |
| Lab investigations | Hemoglobin-9.5 g/dL, platelets - 0.68 lacs/ul, Serum albumin-2.44 g/dL, serum globulin-4.08 g/dL, total bilirubin-ALT-127 IU/L, AST-276 IU/L | Hemoglobin - 8.2 g/dL, platelets – 0.74 lacs/ul, serum albumin -2.44 g/dL, total bilirubin-1.4 mg/dL, AST-124 IU/L, ALT-54 IU/L | Serum albumin-3.8 gm/dL, IgG-21 g/L, total bilirubin-5 mg/dL, ALT-240 IU/L, AST-223 IU/L | Serum albumin-3.8 g/dL, IgG-35 g/L, total bilirubin-5 mg/dL, ALT-175 IU/L, AST-147 IU/L | Hemoglobin-13.3 g/dL, WBC count-3800/ul, total bilirubin-0.6 mg/dL, serum globulin-2.8 mg/dL, ALT-280 IU/L, AST-214 IU/L | Hemoglobin-12.4 g/dL, WBC count-7800/ul, IgG-20.05 g/L, total bilirubin-29.1 mg/dL, ALT-295 IU/L, AST-453 IU/L |
| Autoantibody | Antinuclear antibody 17 profile blot, Anti-centromere antibody (+) | FANA 1280× Anti-centromere (+) | FANA 600× Anti-centromere (+) | FANA 1000× Anti-centromere (+) | FANA 2560× Anti-centromere (+) | FANA 640× Anti-centromere (+) |
| Treatment | Prednisolone 30 mg/day | Prednisolone 30 mg/day with azathioprine | Prednisolone 40 mg/day | Prednisolone 35 mg/day and azathioprine | Not mentioned | Prednisolone 40 mg/day |
| Outcome | Improvement in clinical symptoms and liver function test | Improvement of liver test abnormalities | Marked improvement of liver test abnormalities | Completely normal liver function test | Not mentioned | Complete disappearance of liver test abnormalities |

ALT: alanine aminotransferase; anti-centromere: anti-centromere antibody; AST: aspartate aminotransferase; CREST: calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia syndrome; CRST: calcinosis cutis, Raynaud’s phenomenon, sclerodactyly, telangiectasia syndrome; FANA: fluorescent anti-nuclear antibody; g/dL: grams/deciliter; g/L: Grams/liter; IgG: immunoglobulin G; IU/L: international units/liter; lacs/ul: lacs/microliter; mg/day: milligrams/day; mg/dl: milligrams/deciliter; SSc: systemic sclerosis.

In our case, cirrhosis of the liver due to autoimmune hepatitis and SSc was diagnosed during the current admission. However, her fibroscan of the liver could not be done due to the unavailability of this facility at our rural hospital, and a liver biopsy could not be performed as the patient did not give consent. In the present case, liver involvement was advanced compared to the previous four cases. These previous case reports indicate that patients with SSc are at an increased risk of developing autoimmune hepatitis (Table 2).

This case was diffuse SSc in which the patient had Raynaud’s phenomenon, skin thickening in the hands, feet, and elbows, and salt and pepper pigmentation skin over the back and trunk also, but there were no calcinosis cutis, sclerodactyly, or telangiectasia. High-dose oral corticosteroids and azathioprine are the drugs of choice for treatment as they effectively alleviate symptoms and the outcome of autoimmune hepatitis [18].

Managing autoimmune hepatitis is difficult with diffuse cutaneous SSc patients, as these patients may develop a renal crisis with high-dose steroid therapy [19,20]. Future studies are required to determine the treatment outcome and complications of high-dose steroid therapy for combined autoimmune hepatitis and...
SSc.

Conclusions

Patients with SSc and autoimmune hepatitis should be observed for the development of other autoimmune diseases. A high degree of observation is necessary to diagnose autoimmune hepatitis in patients with SSc as symptoms are non-specific and may appear gradually over years. Patients with SSc should be monitored for liver function tests regularly as early diagnosis and treatment of autoimmune hepatitis will help achieve a reasonable remission rate.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, Mahatma Gandhi Institute of Medical Sciences, Sevagram. Reg. No. ECR/47/Inst/MH/2015/RR-19 issued approval MGIMS/IEC/MED/336/2022. Approved. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Cutolo M, Soldano S, Smith V: Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019, 15:753-64. 10.1080/17446699.2019.164915
2. Johnson PJ, McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993, 18:988-1005. 10.1002/hep.18401805
3. West M, Jasim HE, Medhekar S: The development of connective tissue diseases in patients with autoimmune hepatitis: a case series. Semin Arthritis Rheum. 2006, 35:344-8. 10.1016/j.semarthrit.2005.12.001
4. González-Huerto MS, Delgado-Ayalá LY, Osorio-Núñez AL, Meléndez-Mercado C: Autoimmune associations in a Mexican cohort with primary biliary cholangitis. Rev Gastroenterol Mex (Engl Ed). 2019, 84:130-5. 10.1016/j.rgme.2018.05.008
5. Bawankule S, Kumar S, Gaidhane A, Quazi M, Singh AP: Clinical profile of patients with hepatic encephalopathy in cirrhosis of liver. J Datta Meghe Inst Med Sci Univ. 2019, 14:150-6. 10.4103/jdmimsu.jdmimsu_88_18
6. Jain J, Singh R, Banait S, Verma N, Waghmare S: Magnitude of peripheral neuropathy in cirrhosis of liver patients from central rural India. Ann Indian Acad Neurol. 2014, 17:409-15. 10.4103/0972-2527.144012
7. van den Hoogen F, Khamma D, Fransen J, et al.: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2015, 65:2737-47. 10.1002/art.38098
8. Frech TM, Mar D: Gastrointestinal and hepatic disease in systemic sclerosis. Rheum Dis Clin North Am. 2018, 44:15-28. 10.1016/j.rdc.2017.09.002
9. Cohen S: The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology. 1980, 79:155-66. 10.1016/S0016-5085(80)90001-6
10. Kumar S, Singh J, Rattan S, D’Marino AJ, Cobern S, Jimenez SA: Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther. 2017, 45:883-98. 10.1111/apt.13963
11. Wang CR, Tsai HW: Autoimmune liver diseases in systemic rheumatic diseases. World J Gastroenterol. 2022, 28:2527-45. 10.3748/wjg.v28.i23.2527
12. Banait S, Badole SM, Jain J, Thorat A: Risk factors for chronic liver disease in population of central India: a case-control study from rural India. Egypt Liver J. 2021, 11:1-9. 10.1186/s43066-021-00977-9
13. Hennes EM, Zeniya M, Czaia AJ, et al.: Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008, 48:169-76. 10.1002/hep.22322
14. You BC, Jeong SW, Jang JY, et al.: Liver cirrhosis due to autoimmune hepatitis combined with systemic sclerosis. Korean J Gastroenterol. 2012, 59:48-52. 10.4166/kjg.2012.59.1.48
15. Marie I, Leseur H, Tranvouez JI, François A, Riachi G, Cailleux N, Courtois H: Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome?. Rheumatology (Oxford). 2001, 40:102-6. 10.1093/rheumatology/40.1.102
16. Ishikawa M, Okada J, Shibuya A, Kondo H: Scleroderma renal crisis: risk factors for an increasingly rare organ damage. Intern Med. 1995, 34:6-9. 10.2169/internalmedicine.34.6
17. Yabe H, Noma K, Tada N, Mochizuki S, Nagano M: A case of CREST syndrome with rapidly progressive liver damage. Intern Med. 1992, 31:69-73. 10.2169/internalmedicine.31.69
18. Komori A: Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol. 2021, 27:58-69. 10.3350/cmh.2020.0189
19. Moizadeh P, Kahr K, Siegert E, et al.: Scleroderma renal crisis: risk factors for an increasingly rare organ complication. J Rheumatol. 2020, 47:241-8. 10.3899/jrheum.180582
20. Xu D, Zhu L, Cai R, et al.: A multi-predictor model to predict risk of scleroderma renal crisis in systemic sclerosis: a multicentre, retrospective, cohort study. Clin Exp Rheumatol. 2021, 39:721-6. 10.5556/crjnell/au/016x

2022 Banait et al. Cureus 14(11): e31147. DOI 10.7759/cureus.31147